Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Accounts Payables (2016 - 2025)

Aptevo Therapeutics' Accounts Payables history spans 11 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Accounts Payables fell 37.17% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, down 37.17%, while the annual FY2024 figure was $3.1 million, 23.37% down from the prior year.
  • Accounts Payables for Q3 2025 was $2.2 million at Aptevo Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.4 million in Q1 2021 and bottomed at $2.2 million in Q3 2025.
  • The 5-year median for Accounts Payables is $3.7 million (2024), against an average of $3.8 million.
  • The largest annual shift saw Accounts Payables plummeted 37.99% in 2021 before it soared 49.07% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $3.5 million in 2021, then grew by 1.07% to $3.5 million in 2022, then rose by 13.86% to $4.0 million in 2023, then decreased by 23.37% to $3.1 million in 2024, then dropped by 27.32% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Accounts Payables are $2.2 million (Q3 2025), $2.9 million (Q2 2025), and $3.8 million (Q1 2025).